Cystic Fibrosis: all 1,605 studies

Page 11 of 17. Open to participants first (196), then studies with results posted, then the rest; newest registration first within each.

• Human Papillomavirus and Cervical Dysplasia in Women With Cystic FibrosisCompletedNCT03052556Not applicable
• Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis CenterCompletedNCT03052231Not applicable
• RESULT: Reliable, Emergent Solution Using Liprotamase TreatmentStatus unknownNCT03051490Phase 3
• A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic FibrosisCompletedNCT03045523Phase 2
• Effect of Azithromycin on Fatty Acids in CFStatus unknownNCT03045198Phase 4
• Impact of Early Implementation of Narrative Medicine Techniques on Patient Centered Attitudes of Medical StudentsWithdrawnNCT03041571
• A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic FibrosisCompletedNCT03029455Phase 1
• The Sinonasal Cavity as a Reservoir for Upper Airway Bacterial DevelopmentCompletedNCT03016689
• Longitudinal Assessment of Transient Elastography in Cystic FibrosisCompletedNCT03001388
• A Study of Home Monitoring in Adults With Cystic Fibrosis (HOMECF)CompletedNCT02994706Not applicable
• Prognostic Value of Functional Exercise Test (EFX) in Cystic FibrosisCompletedNCT02994017Not applicable
• Small Circulating RNA as Molecular Markers of Lung Disease in Cystic FibrosisCompletedNCT02992080Not applicable
• MRI to Characterize and Predict CF Liver Disease in PUSH CohortCompletedNCT02979340
• Identification of Predictive Epigenetic Biomarkers of Lung Disease Severity in Cystic FibrosisCompletedNCT02976714Not applicable
• Chest Wall Motion Analysis in DiseaseCompletedNCT02958683
• Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose ToleranceTerminatedNCT02955888Phase 2
• Saline Hypertonic in Preschoolers + CTCompletedNCT02950883Phase 2/3
• A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic FibrosisCompletedNCT02950805Phase 1
• Lung Clearance Index (LCI) in Pediatric Patients With Obstructive Lung DiseaseTerminatedNCT02950116Not applicable
• Multilevel Models of Therapeutic Response in the LungsCompletedNCT02947126Phase 1
• MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)CompletedNCT02934139Phase 1
• Perceived Impact of Art Therapy in Patients With Cystic Fibrosis and in Professional Interdisciplinary Teams Taking Care of Them.CompletedNCT02932657
• A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie CapsuleStatus unknownNCT02929420Phase 4
• Hyperpolarized Xenon Imaging in Patients With Cystic FibrosisWithdrawnNCT02912637
• Inflammatory Markers in Broncho-alveolar Lavage Fluid as Risk Factors for Lung Disease in Infants With Cystic Fibrosis: the I-BALL StudyCompletedNCT02907788
• Adherence to Airway Clearance. Novel Approaches to Improving AdherenceStatus unknownNCT02906826Not applicable
• Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic FibrosisCompletedNCT02894684Phase 4
• Urinary and Anorectal Functional Disorders and Their Impact on CF Adults (PerineoMucoRMO)CompletedNCT02894619
• Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis PatientsTerminatedNCT02888730Phase 3
• DNA Methylation and Lung Disease in Cystic FibrosisCompletedNCT02884622Not applicable
• Early Assessment of Respiratory Function, Inflammation and Bronchial Reshuffle Among Newborns Screened for Cystic FibrosisCompletedNCT02883816Not applicable
• Prospective Study of the Phenotypic Expression of Cystic Fibrosis (CF) Screened Positive Newborns With an Atypical Form of CF (DPAM)CompletedNCT02869932Not applicable
• Intestinal Fatty Acid Binding Protein in Very Low Birth Weight Infants With Meconium ObstructionCompletedNCT02864446
• The Effect of Combination Lumacaftor and Ivacaftor on Markers of HyperglycemiaTerminatedNCT02858843Not applicable
• Lung MRI and Allergic Broncho-pulmonary Aspergillosis in Cystic FibrosisCompletedNCT02853175
• Portal Hypertension and Systemic Endothelial FunctionStatus unknownNCT02850692Not applicable
• Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRIActive, not recruitingNCT02848560
• Contraceptive Practices and Cervical Screening in Women With Cystic FibrosisCompletedNCT02847208
• Impact of Respiratory Viral Infections in Infants With Cystic Fibrosis.CompletedNCT02847156Not applicable
• LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis PatientsTerminatedNCT02840136Not applicable
• Costs of Care and Adherence to Treatment for Cystic FibrosisCompletedNCT02832479
• Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung DiseasesCompletedNCT02831348
• Orkambi Exercise StudyCompletedNCT02821130
• The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic FibrosisCompletedNCT02810691Not applicable
• ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With IvacaftorCompletedNCT02807415
• Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two YearsCompletedNCT02803944
• Virtual Reality for the Reduction of Pain During Venipuncture in Children With CFStatus unknownNCT02802839Not applicable
• LBM & Lung Function in Adolescents With CFCompletedNCT02797912
• Transition From Pediatric to Adult Cystic Fibrosis Care CenterStatus unknownNCT02790879
• Evaluation Of The Pan-microbiome and Host Immune Response in CFCompletedNCT02778750
• Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose IntoleranceCompletedNCT02776098
• Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)TerminatedNCT02769637
• Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic FibrosisCompletedNCT02767297Phase 1/2
• Exercise and Oscillatory Positive Expiratory Pressure Therapy in Cystic FibrosisCompletedNCT02750722Not applicable
• Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung DisordersTerminatedNCT02748798Early Phase 1
• Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With IvacaftorStatus unknownNCT02724527Phase 2
• Cystic Fibrosis Related Diabetes Screening.CompletedNCT02723968Not applicable
• Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®Status unknownNCT02722122Phase 2
• A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric PatientsCompletedNCT02722057
• Improving Outcome Measures For Adult CF ACT TrialsCompletedNCT02721498Not applicable
• Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic FibrosisCompletedNCT02718495Phase 1/2
• The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis.CompletedNCT02717650Not applicable
• Impact of Telerehabilitation Training on Pediatric Cystic Fibrosis Patients: An Exploratory StudyCompletedNCT02715921Not applicable
• Biomarker for Cystic FibrosisTerminatedNCT02710383
• Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)CompletedNCT02707562Phase 2
• The Use of Home Oral Glucose Tolerance Test Kit in Screening Cystic Fibrosis Related DiabetesStatus unknownNCT02703155Not applicable
• Backpack Carrying in Children With Cystic FibrosisCompletedNCT02700282Phase 4
• Increase Tolerance for Exercise and Raise Activity Through Connectedness TrialCompletedNCT02700243Not applicable
• Impact of Art Therapy on Anxiety Identified During Hospitalizations Among Children With Cystic Fibrosis Aged 8 to 13CompletedNCT02693431
• Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)CompletedNCT02690857Phase 2
• Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)CompletedNCT02690519Phase 2
• Mechanisms for Vascular Dysfunction and Exercise Tolerance in CFActive, not recruitingNCT02690064Not applicable
• Non Invasive Ventilation During Physical Training in Cystic FibrosisCompletedNCT02684552Not applicable
• Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)CompletedNCT02684422
• Assessment of Rheological Parameters of Human Sputum.CompletedNCT02682290Not applicable
• Pharmacokinetics of FDL169 in Healthy Female SubjectsCompletedNCT02680418Phase 1
• Integrating Supportive Care in Cystic FibrosisCompletedNCT02668575Not applicable
• Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508delWithdrawnNCT02653027Not applicable
• Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationTerminatedNCT02649751Phase 2
• Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) PatientsCompletedNCT02646995Not applicable
• Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary ExacerbationsCompletedNCT02606487
• Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult VolunteersCompletedNCT02605590Phase 1
• Hepatitis B in Cystic Fibrosis and Latent Tuberculosis RespectivelyWithdrawnNCT02605538Not applicable
• The Short-term Effect of ELTGOL on Pulmonary Ventilation Valued Through Electrical Impedance Tomography in Cystic Fibrosis PatientsStatus unknownNCT02600039Not applicable
• Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis PatientsTerminatedNCT02598999Phase 1
• Upper and Lower Airway Colonization in Cystic Fibrosis Patients After Lung TransplantationStatus unknownNCT02591524Not applicable
• Vitamin D and Microbiota in Cystic FibrosisCompletedNCT02589444Not applicable
• Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR MutationCompletedNCT02589236Phase 2
• Glucose Tolerance in Children With Cystic FibrosisCompletedNCT02569229
• Induction of Neutrophilic Traps ( NETs ) by the Environment and Infectious Inflammatory Lung Cystic FibrosisCompletedNCT02564393
• Puberty in Girls Followed for Cystic FibrosisCompletedNCT02562911
• Asthma With Hypersecretion-associated Gene for Cystic FibrosisCompletedNCT02558127
• Special Drug Use Investigation of Ciproxan Injection in PediatricsCompletedNCT02555059
• Video Game Exercise Effectiveness of a Domiciliary Pulmonary Rehabilitation Program in Cystic Fibrosis PatientsCompletedNCT02552043Not applicable
• Analysis T Cells Response for Identification of Aspergillus Bronchitis With Cystic Fibrosis PatientsTerminatedNCT02550041Not applicable
• Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic FibrosisWithdrawnNCT02547116Phase 4
• Comparison of Amikacin Lung Delivery With Two NebulizersStatus unknownNCT02538588Not applicable
• 6 Minute Walk Test in Cystic FibrosisCompletedNCT02538575Not applicable
• Evaluation of Nebulization and Positive Expiratory Pressure CombinationStatus unknownNCT02535130Not applicable
• Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results StratifiedCompletedNCT02526004Not applicable

← Cystic Fibrosis overview